SCHEMBL2392414

SCHEMBL2392414

CCN(CC1CCCC1)c1nc2ccc(C)cc2cc1C=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.45
KDM4E B2RXH2 3/20 0.45
GAA P10253 1/20 0.45
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
RXFP1 Q9HBX9 1/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
OPRK1 P41145 4/20 0.36
CRHR1 P34998 4/20 0.34
NPSR1 Q6W5P4 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
FFAR2 O15552 1/20 0.33
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33
LMNA P02545 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2393935 0.87 ALDH1A1 (0.45) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL5623938 0.86 ALDH1A1 (0.46) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL2395691 0.85 ALDH1A1 (0.41) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL2394735 0.84 CSNK1D (0.39) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL4195023 0.84 ALDH1A1 (0.34) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL2393581 0.82 FFAR2 (0.35) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL4189946 0.81 ALDH1A1 (0.40) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL2395175 0.81 CRHR1 (0.36) ALDH1A1MAPTCNR1CNR2CRHR1
SCHEMBL5047938 0.78 RXFP1 (0.38) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL2393729 0.78 FFAR2 (0.35) ALDH1A1KDM4EMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2138489-B9 NOVEL PYRIMIDINE COMPOUND HAVING BENZYL(HETEROCYCLICMETHYL)AMINE STRUCTURE AND PHARMACEUTICAL PRODUCT CONTAINING THE SAME KOWA CO (JP) 2012-10-24 EP disclosed
EP-2138489-B1 NOVEL PYRIMIDINE COMPOUND HAVING BENZYL(HETEROCYCLICMETHYL)AMINE STRUCTURE AND PHARMACEUTICAL PRODUCT CONTAINING THE SAME KOWA CO (JP) 2012-07-11 EP disclosed
US-8012989-B2 Substituted pyrimidine compounds and their utility as CETP inhibitors KOWA COMPANY, LTD. (JP) 2011-09-06 US disclosed
US-20100249148-A1 NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME KOWA COMPANY, LTD. (JP) 2010-09-30 US disclosed
US-7790737-B2 Substituted pyrimidine compounds and their utility as CETP inhibitors KOWA COMPANY, LTD. (JP) 2010-09-07 US disclosed
EP-2138489-A1 NOVEL PYRIMIDINE COMPOUND HAVING BENZYL(HETEROCYCLICMETHYL)AMINE STRUCTURE AND PHARMACEUTICAL PRODUCT CONTAINING THE SAME Kowa Company. Ltd. (JP) 2009-12-30 EP disclosed
US-20090062306-A1 NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME KOWA COMPANY, LTD. (JP) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249148-A1 NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME CETP, MTTP, NPC1L1 ALDH1A1 4006/4885KDM4E 2087/4885GAA 4017/4885
US-20090062306-A1 NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME CETP, MTTP, NPC1L1 ALDH1A1 4006/4885KDM4E 2087/4885GAA 4017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.